Sequential advanced pharmacy practice experiences at one institution for students from three pharmacy schools.

PURPOSE: The structure and implementation of an advanced pharmacy practice experience (APPE) that was sequential in nature are described. SUMMARY: In early 2008, the pharmacy department of the Cleveland Clinic began conversations with three partner pharmacy schools in the surrounding area to accommodate rotations for advanced practice experiences pharmacy students. The resulting sequential APPE (SAE) program is offered at each school for four or five months and incorporates a longitudinal student project component to be completed over the SAE's duration. Program coordination and scheduling are unique to this program, where rotations are set up outside of the typical rotation selection. Since 2009, 23 students have completed the program, and 10 are currently enrolled. The SAE program was implemented in 2009 and continues to provide a depth of experience for pharmacy students. Preceptors have reported that SAE students are more motivated, have goals that fit with the institution, and offer decreased orientation burden compared with traditional APPE students. Students report a maximum of 19 hours gained per month in decreased orientation time to the computer system and site, allowing them to focus more time on patient care. Over a five-month period, a student could gain 76 hours in clinical experience over the traditional APPE student due to the decreased orientation burden. CONCLUSION: SAEs at one institution have proven advantageous to preceptors, students, and the site. SAEs have provided enriching student rotations while increasing site efficiencies, allowing longitudinal projects, and enhancing the site's exposure to students as potential residency candidates.

Antibacterial treatment strategies in hospitalized patients: what role for pharmacoeconomics?

Antimicrobial agents continue to account for a significant portion of institutional pharmaceutical expenditures. Pharmacoeconomic analysis is a valuable tool in assessing antibacterial agents for their place in institutional formularies. This article reviews various types of pharmacoeconomic analyses, their respective limitations, and their roles in the antibacterial formulary decision-making process. We also discuss the current state of the antibacterial pharmacoeconomic literature, including the economic impact of antimicrobial resistance.